Plaque Psoriasis
Conditions
Brief summary
MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®. The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis of moderate and severe degree.
Detailed description
Adalimumab is a recombinant humanized monoclonal antibody currently being developed by Mabscale LLC, as a proposed biosimilar to Humira®, which is approved as treatment in patients with chronic plaque psoriasis. This randomized equivalence study is designed to meet the regulatory requirement for approval of a biosimilar product.
Interventions
DRUGAdalimumab
Adalimumab injection 40 mg / 0.8 ml
DRUGHumira
Adalimumab injection 40 mg / 0.4 ml
Sponsors
Mabscale, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Written informed consent. 2. Male and female patients aged 18-65 years, body weight ≥ 50 kg and ≤ 120 kg. 3. Established clinical diagnosis plaque psoriasis, lasting at least 6 months before the screening. 4. Plaque psoriasis of moderate or severe severity of stable course with: * PASI ≥ 12 points; * BSA ≥ 10 %; * sPGA ≥ 3 points. 5. Patients who have been shown to undergo systemic therapy and/or patients who have had insufficient therapeutic efficacy of at least 1 previous standard systemic therapy for psoriasis, including phototherapy, therapy with cytostatic and immunosuppressive drugs, or who have had intolerance to standard systemic therapy.
Exclusion criteria
1. Data on intolerance or hypersensitivity to any components of the drugs, or to any other human proteins, immunoglobulin preparations. 2. A history of severe hypersensitivity reactions of any etiology. 3. Other (other than plaque) forms of psoriasis. 4. Drug-induced psoriasis. 5. Data on the use of the Adalimumab or any preparations of monoclonal antibodies inhibiting TNF-α at any time during life. 6. The presence of Adalimumab antibodies. 7. Extensive surgical intervention performed less than 30 days before the screening period, or planned extensive surgical intervention during the study period. 8. Active or latent tuberculosis 9. Lymphoproliferative diseases, lymphoma, leukemia, myeloproliferative diseases or a history of multiple myeloma. 10. Any other malignant neoplasms currently or in anamnesis within the last 5 years, with the exception of completely removed and/or cured. 11. Confirmed coronavirus infection caused by COVID-19 within 8 weeks prior to the screening period. 12. Anamnestic data on the presence of syphilis, viral hepatitis B, viral hepatitis C, HIV. 13. Vaccination with live or attenuated vaccines within 8 weeks before the screening period. 14. Hepatic and/or renal insufficiency. 15. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients who achieved a response according to the PASI criterion of 75 (a decrease in the severity and prevalence of psoriasis by ≥75% from the baseline level assessed by the PASI index) | after 16 weeks of therapy (assessment at Visit 10) |
| Proportion of patients with positive antibody titer to Adalimumab | 51 weeks of therapy |
| Percentage of patients who have neutralizing antibodies to Adalimumab | 51 weeks of therapy |
Countries
Russia
Contacts
Primary ContactYulia BASKAEVA
Outcome results
None listed